AAPL326.59-7.15 (-2.14%) ▼|ABBV253.38-1.11 (-0.44%) ▼|ABT101.66+0.98 (+0.97%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|AAPL326.59-7.15 (-2.14%) ▼|ABBV253.38-1.11 (-0.44%) ▼|ABT101.66+0.98 (+0.97%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|
22.7 C
New York
Tuesday, July 21, 2026

Tag: monoclonal antibody

newssourceFORcompanyinformationcontent1releasesmarket

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients...

PRESS RELEASE 

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio’s recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the “Board”) and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units (“RSUs”) for 153,505 shares of common stock (together, the “Inducement Awards”). The Inducement Awards were granted as inducements material to Dr. Yarema entering into employment with ImageneBio in accordance with Nasdaq Listing Rule 5635(c)(4).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMonoclonal antibody

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers